158 related articles for article (PubMed ID: 38388922)
1. ARG1 Is a Potential Prognostic Marker in Metastatic Endometrial Cancer.
Tran DN; Rozen V; Nguyen LTK; Jung JS; Coghill LM; Hunter MI; Kim TH; Yoo JY; Jeong JW
Reprod Sci; 2024 Jun; 31(6):1632-1641. PubMed ID: 38388922
[TBL] [Abstract][Full Text] [Related]
2. ARG1 is a potential prognostic marker in metastatic and recurrent endometrial cancer.
Tran DN; Rozen V; Hunter MI; Kim TH; Jeong JW
Res Sq; 2023 Jul; ():. PubMed ID: 37503068
[TBL] [Abstract][Full Text] [Related]
3. PTEN expression in endometrial hyperplasia and risk of cancer: a systematic review and meta-analysis.
Raffone A; Travaglino A; Saccone G; Viggiani M; Giampaolino P; Insabato L; Mollo A; De Placido G; Zullo F
Arch Gynecol Obstet; 2019 Jun; 299(6):1511-1524. PubMed ID: 30915635
[TBL] [Abstract][Full Text] [Related]
4. PTEN mutation: A potential prognostic factor associated with immune infiltration in endometrial carcinoma.
Tao Y; Liang B
Pathol Res Pract; 2020 Jun; 216(6):152943. PubMed ID: 32279917
[TBL] [Abstract][Full Text] [Related]
5. The synergistic effect of Mig-6 and Pten ablation on endometrial cancer development and progression.
Kim TH; Franco HL; Jung SY; Qin J; Broaddus RR; Lydon JP; Jeong JW
Oncogene; 2010 Jul; 29(26):3770-80. PubMed ID: 20418913
[TBL] [Abstract][Full Text] [Related]
6. Endometrial tumorigenesis in Pten(+/-) mice is independent of coexistence of estrogen and estrogen receptor α.
Joshi A; Wang H; Jiang G; Douglas W; Chan JS; Korach KS; Ellenson LH
Am J Pathol; 2012 Jun; 180(6):2536-47. PubMed ID: 22503752
[TBL] [Abstract][Full Text] [Related]
7. Significance of a PTEN Mutational Status-Associated Gene Signature in the Progression and Prognosis of Endometrial Carcinoma.
Wu Y; Wang J; Ge L; Hu Q
Oxid Med Cell Longev; 2022; 2022():5130648. PubMed ID: 35251475
[TBL] [Abstract][Full Text] [Related]
8. Genetic derangements in the tumor suppressor gene PTEN in endometrial precancers as prognostic markers for cancer development: a population-based study from northern Norway with long-term follow-up.
Orbo A; Kaino T; Arnes M; Kopp M; Eklo K
Gynecol Oncol; 2004 Oct; 95(1):82-8. PubMed ID: 15385114
[TBL] [Abstract][Full Text] [Related]
9. Mutational analysis of the PTEN gene in endometrial carcinoma and hyperplasia.
Sun H; Enomoto T; Fujita M; Wada H; Yoshino K; Ozaki K; Nakamura T; Murata Y
Am J Clin Pathol; 2001 Jan; 115(1):32-8. PubMed ID: 11190805
[TBL] [Abstract][Full Text] [Related]
10. Loss of PTEN expression as diagnostic marker of endometrial precancer: A systematic review and meta-analysis.
Raffone A; Travaglino A; Saccone G; Campanino MR; Mollo A; De Placido G; Insabato L; Zullo F
Acta Obstet Gynecol Scand; 2019 Mar; 98(3):275-286. PubMed ID: 30511743
[TBL] [Abstract][Full Text] [Related]
11. Loss of expression of MLH1, MSH2, MSH6, and PTEN related to endometrial cancer in 68 patients with endometrial hyperplasia.
Orbo A; Nilsen MN; Arnes MS; Pettersen I; Larsen K
Int J Gynecol Pathol; 2003 Apr; 22(2):141-8. PubMed ID: 12649668
[TBL] [Abstract][Full Text] [Related]
12. Association of mammalian target of rapamycin with aggressive type II endometrial carcinomas and poor outcome: a potential target treatment.
Peiró G; Peiró FM; Ortiz-Martínez F; Planelles M; Sánchez-Tejada L; Alenda C; Ceballos S; Sánchez-Payá J; Laforga JB
Hum Pathol; 2013 Feb; 44(2):218-25. PubMed ID: 22955108
[TBL] [Abstract][Full Text] [Related]
13. PTEN mutations as predictive marker for the high-grade endometrial cancer development in slovak women.
Gbelcová H; Gergely L; Šišovský V; Straka Ľ; Böhmer D; Pastoráková A; Sušienková K; Repiská V; Korbeľ M; Danihel Ľ; Priščáková P
Physiol Res; 2022 Dec; 71(Suppl 1):S125-S135. PubMed ID: 36592448
[TBL] [Abstract][Full Text] [Related]
14. Expression and significance of beta-catenin, Glut-1 and PTEN in proliferative endometrium, endometrial intraepithelial neoplasia and endometrioid adenocarcinoma.
Xiong Y; Xiong YY; Zhou YF
Eur J Gynaecol Oncol; 2010; 31(2):160-4. PubMed ID: 20527231
[TBL] [Abstract][Full Text] [Related]
15. lncRNA OIP5-AS1 Suppresses Cell Proliferation and Invasion of Endometrial Cancer by Regulating PTEN/AKT via Sponging miR-200c-3p.
Liu Y; Cai X; Cai Y; Chang Y
J Immunol Res; 2021; 2021():4861749. PubMed ID: 34368370
[TBL] [Abstract][Full Text] [Related]
16. Suppressive effect of microRNA-449a on the NDRG1/PTEN/AKT axis regulates endometrial cancer growth and metastasis.
Wu AY; Hu Y; Cang W; Li D; Wang WJ; Tian Q; Gu LY; Zhang N; Ji F; Qiu LH
Exp Cell Res; 2019 Sep; 382(2):111468. PubMed ID: 31201812
[TBL] [Abstract][Full Text] [Related]
17. The role of biomarkers in endometrial cancer and hyperplasia: a literature review.
Hutt S; Tailor A; Ellis P; Michael A; Butler-Manuel S; Chatterjee J
Acta Oncol; 2019 Mar; 58(3):342-352. PubMed ID: 30614360
[TBL] [Abstract][Full Text] [Related]
18. Mig-6 suppresses endometrial cancer associated with Pten deficiency and ERK activation.
Kim TH; Yoo JY; Kim HI; Gilbert J; Ku BJ; Li J; Mills GB; Broaddus RR; Lydon JP; Lim JM; Yoon HG; Jeong JW
Cancer Res; 2014 Dec; 74(24):7371-82. PubMed ID: 25377472
[TBL] [Abstract][Full Text] [Related]
19. [Expression of beta-catenin, Glut-1, PTEN proteins in uterine endometrioid adenocarcinoma and its precursor lesions].
Xiong Y; Xiong YY; Zhou YF
Zhonghua Bing Li Xue Za Zhi; 2009 Sep; 38(9):594-9. PubMed ID: 20079187
[TBL] [Abstract][Full Text] [Related]
20. Expression of PTEN and β-Catenin and Their Relationship With Clinicopathological and Prognostic Factors in Endometrioid Type Endometrial Cancer.
Sal V; Demirkiran F; Erenel H; Tokgozoglu N; Kahramanoglu I; Bese T; Turan H; Sofiyeva N; Calay Z; Arvas M; Guralp O
Int J Gynecol Cancer; 2016 Mar; 26(3):512-20. PubMed ID: 26894937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
